Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$53.30

-0.1401 (-0.26%)

14:07
04/21/17
04/21
14:07
04/21/17
14:07

Bristol-Myers receives 'positive' CHMP opinion on Opdivo approval

Bristol-Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. Opdivo is the first and only PD-1 immune checkpoint inhibitor for the treatment of patients with previously treated mUC to receive a positive CHMP opinion. Opdivo is already approved by the EC for six indications in four distinct tumor types. "We view the CHMP recommendation of Opdivo for previously treated locally advanced or metastatic urothelial carcinoma as an important milestone for the patients. Bristol-Myers Squibb looks forward to collaborating with the European Commission as it considers this potential new indication for Opdivo," said Murdo Gordon, executive vice president and chief commercial officer, Bristol-Myers Squibb.

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

BMY Bristol-Myers
$53.30

-0.1401 (-0.26%)

03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
04/03/17
LEER
04/03/17
NO CHANGE
Target $141
LEER
Outperform
Incyte price target raised to $141 from $130 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $141 from $130 as he sees epacadostat better positioned in the emerging IO combination landscape. The analyst notes that the company and Bristol-Myers (BMY) have announced that both companies will advance the combination of Opdivo and epacadostat into several registration trials in 2017. He reiterates an Outperform rating on Incyte's shares.
04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$20.13

-0.4 (-1.95%)

14:50
07/21/17
07/21
14:50
07/21/17
14:50
Options
Defensive option play in Twitter ahead of earnings next week »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 13

    Sep

GS

Goldman Sachs

$220.60

-1.7 (-0.76%)

14:47
07/21/17
07/21
14:47
07/21/17
14:47
Conference/Events
Goldman Sachs to hold a conference call »

EVP & CFO Chavez and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 17

    Oct

RL

Ralph Lauren

$74.91

1.15 (1.56%)

14:45
07/21/17
07/21
14:45
07/21/17
14:45
Options
Ralph Lauren call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 10

    Aug

WHLR

Wheeler REIT

$11.01

0.28 (2.61%)

14:41
07/21/17
07/21
14:41
07/21/17
14:41
Hot Stocks
NS Advisors reports 5.4% stake in Wheeler REIT »

Recently, NS Advisors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

BKJ

Bancorp of New Jersey

$16.80

-0.2 (-1.18%)

14:30
07/21/17
07/21
14:30
07/21/17
14:30
Hot Stocks
Breaking Hot Stocks news story on Bancorp of New Jersey »

Clover Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMPH

Amphastar

$17.92

0.18 (1.01%)

, MNTA

Momenta

$17.25

0.35 (2.07%)

14:29
07/21/17
07/21
14:29
07/21/17
14:29
Recommendations
Amphastar, Momenta, Novartis analyst commentary  »

Amphastar…

AMPH

Amphastar

$17.92

0.18 (1.01%)

MNTA

Momenta

$17.25

0.35 (2.07%)

NVS

Novartis

$84.78

-0.64 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 17

    May

MNTA

Momenta

$17.25

0.35 (2.07%)

14:22
07/21/17
07/21
14:22
07/21/17
14:22
Hot Stocks
Momenta: Jury finds patent on Lovenox manufacturing infringed but invalid »

Momenta Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

WLL

Whiting Petroleum

$5.02

-0.0951 (-1.86%)

14:20
07/21/17
07/21
14:20
07/21/17
14:20
Options
Second day of interest in Whiting Petroleum Jan 8 calls »

Second day of interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

$NSD

NASDAQ Market Internals

14:17
07/21/17
07/21
14:17
07/21/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
07/21/17
07/21
14:16
07/21/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAST

Fastenal

$43.07

0.39 (0.91%)

14:15
07/21/17
07/21
14:15
07/21/17
14:15
Options
Fastenal put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
07/21/17
07/21
14:15
07/21/17
14:15
General news
Treasury Action: supply complicates trading in the coming week »

Treasury Action: supply…

14:10
07/21/17
07/21
14:10
07/21/17
14:10
General news
NY Fed's overnight reverse repo totaled $122.7 B, with 37 counterparties »

NY Fed's overnight…

IWM

iShares Trust Russell 2000 Index Fund

$142.55

-0.65 (-0.45%)

, RUT

Russell 2000 Index

14:08
07/21/17
07/21
14:08
07/21/17
14:08
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT)…

IWM

iShares Trust Russell 2000 Index Fund

$142.55

-0.65 (-0.45%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$246.68

-0.42 (-0.17%)

, SPX

S&P 500

14:07
07/21/17
07/21
14:07
07/21/17
14:07
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX)…

SPY

SPDR S&P 500 ETF Trust

$246.68

-0.42 (-0.17%)

SPX

S&P 500

AAPL

Apple

$150.34

-0.68 (-0.45%)

IBM

IBM

$146.68

-0.98 (-0.66%)

XLK

Technology Select Sector SPDR

$57.38

-0.16 (-0.28%)

XLU

Utilities SPDR

$52.98

0.065 (0.12%)

XLV

Health Care Select Sector SPDR

$81.00

-0.08 (-0.10%)

XLP

Consumer Staples Sector SPDR

$54.98

-0.01 (-0.02%)

XLE

Energy Select Sector SPDR

$65.26

-0.5 (-0.76%)

XLF

Financial Select Sector

$24.85

0.05 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

14:05
07/21/17
07/21
14:05
07/21/17
14:05
General news
FX Action: USD-JPY »

FX Action: USD-JPY posted…

ECA

Encana

$9.95

0.28 (2.90%)

14:00
07/21/17
07/21
14:00
07/21/17
14:00
Options
Encana with a large call ratio spread as a bullish play is adjusted »

Encana with a large call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

TJX

TJX

$68.63

-0.97 (-1.39%)

13:55
07/21/17
07/21
13:55
07/21/17
13:55
Options
TJX put volume heavy and directionally bearish »

Bearish flow noted in TJX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$8.50

0.12 (1.43%)

, SFTBF

SoftBank

$83.15

-0.02 (-0.02%)

13:53
07/21/17
07/21
13:53
07/21/17
13:53
Periodicals
Sprint enters into partnership talks with Comcast, Charter, Nikkei reports »

SoftBank (SFTBF)…

S

Sprint

$8.50

0.12 (1.43%)

SFTBF

SoftBank

$83.15

-0.02 (-0.02%)

CMCSA

Comcast

$39.49

0.15 (0.38%)

CMCSK

Comcast

TMUS

T-Mobile

$61.12

-0.85 (-1.37%)

CHTR

Charter

$345.30

-1.31 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 27

    Jul

  • 01

    Aug

  • 03

    Aug

  • 08

    Aug

  • 14

    Aug

BTG

B2Gold

$2.75

0.04 (1.48%)

13:40
07/21/17
07/21
13:40
07/21/17
13:40
Options
In the money call write in B2Gold »

In the money call write…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$26.30

-0.2 (-0.75%)

13:37
07/21/17
07/21
13:37
07/21/17
13:37
Hot Stocks
Mid Penn Bancorp receives regulatory clearance to open Halifax branch »

Mid Penn Bank, subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRG

NRG Energy

$24.20

0.089 (0.37%)

13:30
07/21/17
07/21
13:30
07/21/17
13:30
Options
Notable new position opened in NRG options »

Notable new position…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

13:30
07/21/17
07/21
13:30
07/21/17
13:30
General news
Action Economics Survey results: »

Action Economics Survey…

HAIN

Hain Celestial

$42.79

1.05 (2.52%)

13:23
07/21/17
07/21
13:23
07/21/17
13:23
Conference/Events
Hain Celestial management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

VIX

Volatility Index S&P 500 Options

13:20
07/21/17
07/21
13:20
07/21/17
13:20
Options
Impressive 3-way boosts VIX option volume by a million contracts »

Impressive 3-way boosts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.